Stock 688389 SHENZHEN LIFOTRONIC TECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Shenzhen Lifotronic Technology Co., Ltd.

Equities

688389

CNE100005WZ5

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 23/05/2024 BST 		5-day change 1st Jan Change
18.93 CNY -2.82% Intraday chart for Shenzhen Lifotronic Technology Co., Ltd. -8.33% -15.90%
02-22 Shenzhen Lifotronic Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Shenzhen Lifotronic Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
SHENZHEN LIFOTRONIC TECHNOLOGY CO., LTD. Stock Shenzhen Lifotronic Technology Co., Ltd.
-15.90% 1.12B -
BIOMÉRIEUX Stock bioMérieux
-4.92% 12.27B
B+
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-5.82% 7.99B
B-
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+5.43% 5.69B
B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+26.16% 5.42B
C
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-9.58% 4.13B
C
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-59.63% 2.7B
D+
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+8.44% 2.6B - -
VITROLIFE AB Stock Vitrolife AB
-3.70% 2.38B
B-
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+21.00% 2.1B
C
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. 688389 Stock
  4. Ratings Shenzhen Lifotronic Technology Co., Ltd.